{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:18:14Z","timestamp":1785417494101,"version":"3.56.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4t Augsburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Lynch syndrome (LS) is not considered part of childhood cancer predisposition syndromes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Analysis of a pediatric osteosarcoma (OS) displayed hypermutation (16.8), alternative lengthening of telomeres (ALT), loss of PMS2 expression in tumor tissue (retained in non-neoplastic cells), <jats:italic>PMS2<\/jats:italic> loss of heterozygosity (LOH), and high-degree of microsatellite instability (MSI) tested by PCR. A heterozygous duplication c.1076dup p.(Leu359Phefs*6) in exon 10 of NM_000535.6:<jats:italic>PMS2<\/jats:italic> was detected by SNV analysis in peripheral blood, confirming diagnosis of LS in the patient. The tumor molecular features suggest LS-associated development of OS. In a second case, whole-genome sequencing identified a heterozygous SNV c.1\u00a0A\u2009&gt;\u2009T p.? in exon 1 of <jats:italic>PMS2<\/jats:italic> in tumor and germline material of a girl with ependymoma. Tumor analysis displayed evidence for ALT and low mutational burden (0.6), PMS2 expression was retained, MSI was low. Multiplex ligation-dependent probe amplification identified no additional <jats:italic>PMS2<\/jats:italic> variant and germline MSI testing did not reveal increased gMSI ratios in the patient\u00b4s lymphocytes. Thus, CMMRD was most closely excluded and our data do not suggest that ependymoma was related to LS in the child.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our data suggest that the LS cancer spectrum may include childhood cancer. The importance of LS in pediatric cancers necessitates prospective data collection. Comprehensive molecular workup of tumor samples is necessary to explore the causal role of germline genetic variants.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13053-023-00254-4","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T08:01:49Z","timestamp":1686556909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Beyond germline genetic testing - heterozygous pathogenic variants in PMS2 in two children with Osteosarcoma and Ependymoma"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4577-0503","authenticated-orcid":false,"given":"Michaela","family":"Kuhlen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2477-9277","authenticated-orcid":false,"given":"Mariola Monika","family":"Golas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2295-8810","authenticated-orcid":false,"given":"Tina","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8237-1854","authenticated-orcid":false,"given":"Michael C.","family":"Fr\u00fchwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"issue":"24","key":"254_CR1","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","volume":"373","author":"J Zhang","year":"2015","unstructured":"Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in Pediatric Cancer. N Engl J Med. 2015;373(24):2336\u201346.","journal-title":"N Engl J Med"},{"issue":"7696","key":"254_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Grobner","year":"2018","unstructured":"Grobner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555(7696):321\u20137.","journal-title":"Nature"},{"issue":"4","key":"254_CR3","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/ajmg.a.38142","volume":"173","author":"T Ripperger","year":"2017","unstructured":"Ripperger T, Bielack SS, Borkhardt A, Brecht IB, Burkhardt B, Calaminus G, et al. Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet A. 2017;173(4):1017\u201337.","journal-title":"Am J Med Genet A"},{"key":"254_CR4","doi-asserted-by":"crossref","unstructured":"Mirabello L, Yeager M, Mai PL, Gastier-Foster JM, Gorlick R, Khanna C et al. Germline TP53 variants and susceptibility to osteosarcoma. J Natl Cancer Inst. 2015;107(7).","DOI":"10.1093\/jnci\/djv101"},{"key":"254_CR5","doi-asserted-by":"crossref","unstructured":"Mirabello L, Zhu B, Koster R, Karlins E, Dean M, Yeager M et al. Frequency of pathogenic germline variants in Cancer-Susceptibility genes in patients with Osteosarcoma. JAMA Oncol. 2020.","DOI":"10.1001\/jamaoncol.2020.0197"},{"issue":"3","key":"254_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S0090-3019(97)00299-1","volume":"49","author":"KJ Mullins","year":"1998","unstructured":"Mullins KJ, Rubio A, Myers SP, Korones DN, Pilcher WH. Malignant ependymomas in a patient with Turcot\u2019s syndrome: case report and management guidelines. Surg Neurol. 1998;49(3):290\u20134.","journal-title":"Surg Neurol"},{"issue":"1","key":"254_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/(SICI)1096-911X(199701)28:1<59::AID-MPO11>3.0.CO;2-5","volume":"28","author":"CF Torres","year":"1997","unstructured":"Torres CF, Korones DN, Pilcher W. Multiple ependymomas in a patient with Turcot\u2019s syndrome. Med Pediatr Oncol. 1997;28(1):59\u201361.","journal-title":"Med Pediatr Oncol"},{"issue":"11","key":"254_CR8","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/2159-8290.CD-21-0094","volume":"11","author":"CM van Tilburg","year":"2021","unstructured":"van Tilburg CM, Pfaff E, Pajtler KW, Langenberg KPS, Fiesel P, Jones BC, et al. The Pediatric Precision Oncology INFORM Registry: clinical outcome and benefit for patients with very high-evidence targets. Cancer Discov. 2021;11(11):2764\u201379.","journal-title":"Cancer Discov"},{"issue":"6","key":"254_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/humu.22311","volume":"34","author":"D Ingham","year":"2013","unstructured":"Ingham D, Diggle CP, Berry I, Bristow CA, Hayward BE, Rahman N, et al. Simple detection of germline microsatellite instability for diagnosis of constitutional mismatch repair cancer syndrome. Hum Mutat. 2013;34(6):847\u201352.","journal-title":"Hum Mutat"},{"key":"254_CR10","doi-asserted-by":"crossref","unstructured":"Peltomaki P. Update on Lynch syndrome genomics. Familial cancer. 2016.","DOI":"10.1007\/s10689-016-9882-8"},{"issue":"1","key":"254_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0004.2009.01230.x","volume":"76","author":"HT Lynch","year":"2009","unstructured":"Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76(1):1\u201318.","journal-title":"Clin Genet"},{"issue":"11","key":"254_CR12","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/jnci\/djac151","volume":"114","author":"CP Kratz","year":"2022","unstructured":"Kratz CP, Smirnov D, Autry R, Jager N, Waszak SM, Grosshennig A, et al. Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene pathogenic variants in children and adolescents with Cancer. J Natl Cancer Inst. 2022;114(11):1523\u201332.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"254_CR13","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(16)30147-4","volume":"17","author":"ML Ballinger","year":"2016","unstructured":"Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, et al. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016;17(9):1261\u201371.","journal-title":"Lancet Oncol"},{"key":"254_CR14","doi-asserted-by":"crossref","unstructured":"de Angelis de Carvalho N, Niitsuma BN, Kozak VN, Costa FD, de Macedo MP, Kupper BEC et al. Clinical and molecular Assessment of patients with Lynch Syndrome and Sarcomas Underpinning the Association with MSH2 germline pathogenic variants. Cancers (Basel). 2020;12(7).","DOI":"10.3390\/cancers12071848"},{"issue":"1","key":"254_CR15","first-page":"vdz033","volume":"1","author":"L Guerrini-Rousseau","year":"2019","unstructured":"Guerrini-Rousseau L, Varlet P, Colas C, Andreiuolo F, Bourdeaut F, Dahan K, et al. Constitutional mismatch repair deficiency-associated brain tumors: report from the european C4CMMRD consortium. Neurooncol Adv. 2019;1(1):vdz033.","journal-title":"Neurooncol Adv"},{"issue":"4","key":"254_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/(SICI)1097-0215(19960208)65:4<422::AID-IJC4>3.0.CO;2-Z","volume":"65","author":"HF Vasen","year":"1996","unstructured":"Vasen HF, Sanders EA, Taal BG, Nagengast FM, Griffioen G, Menko FH, et al. The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC). Int J cancer J Int du cancer. 1996;65(4):422\u20135.","journal-title":"Int J cancer J Int du cancer"},{"key":"254_CR17","doi-asserted-by":"crossref","unstructured":"Briggs M, Das A, Firth H, Levine A, Sanchez-Ramirez S, Negm L et al. Recurrent posterior fossa group A (PFA) ependymoma in a young child with constitutional mismatch repair deficiency (CMMRD). Neuropathol Appl Neurobiol. 2022:e12862.","DOI":"10.1111\/nan.12862"},{"issue":"1","key":"254_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","volume":"22","author":"M Dominguez-Valentin","year":"2020","unstructured":"Dominguez-Valentin M, Sampson JR, Seppala TT, Ten Broeke SW, Plazzer JP, Nakken S, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective Lynch Syndrome Database. Genet medicine: official J Am Coll Med Genet. 2020;22(1):15\u201325.","journal-title":"Genet medicine: official J Am Coll Med Genet"},{"issue":"29","key":"254_CR19","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.2018.78.4777","volume":"36","author":"SW Ten Broeke","year":"2018","unstructured":"Ten Broeke SW, van der Klift HM, Tops CMJ, Aretz S, Bernstein I, Buchanan DD, et al. Cancer Risks for PMS2-Associated Lynch Syndrome. J Clin oncology: official J Am Soc Clin Oncol. 2018;36(29):2961\u20138.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-023-00254-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-023-00254-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-023-00254-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T08:07:06Z","timestamp":1686557226000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-023-00254-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["254"],"URL":"https:\/\/doi.org\/10.1186\/s13053-023-00254-4","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"assertion":[{"value":"28 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient (CR1) and parents (CR1 and CR2) provided informed consent on publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"8"}}